Overview

A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time

Status:
Not yet recruiting

Trial end date:
2020-04-01

Target enrollment:

Participant gender:

Summary

Atazanavir (ATV) and cobicistat (COBI) are approved for use with other drugs for the treatment of HIV-1 (human immunodeficiency virus Type 1) infection in adults. The positive effect of patients taking both these drugs led to the development of a combination tablet (EVOTAZ®), which can help reduce the number of pills a patient has to take and improves their adherence with HIV therapy. This study compares the amount of ATV and COBI in the bodies of healthy adult volunteers when taken as a combination formulation, and when ATV is administered as an oral powder at the same time as COBI administered as an oral tablet. The ATV/COBI combination formulation and ATV powder will be taken with food.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Atazanavir Sulfate
Cobicistat